Trial Profile
Phase II study to evaluate the efficacy and tolerability of fulvestrant 250mg, 250mg plus 500mg loading regimen and 500mg in postmenopausal women with ER +ve advanced breast cancer progressing or relapsing after previous endocrine therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2020
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms FINDER-II
- Sponsors AstraZeneca
- 08 May 2019 Status changed from active, no longer recruiting to completed.
- 22 Apr 2019 The trial has been completed in Belgium, Czech Republic and Hungary.
- 08 Feb 2019 Planned End Date changed from 2 Jan 2019 to 2 Jan 2020.